Ormat Technologies (ORA) 49.04 $ORA Zacks.com featured

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ormat Technologies (ORA) 49.04 $ORA

Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks
BCC: 26.41 (+0.35), ATVI: 42.80 (+0.65), ORA: 49.04 (+0.52), UBNT: 53.17 (+1.10), LGND: 106.19 (-0.85)

5 Stocks to Play Momentum the Driehaus Way
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:53AM CDT
Momentum strategies that have the potential to offer healthy returns have always been the on radar of investors with a high risk appetite.
BCC: 26.41 (+0.35), ATVI: 42.80 (+0.65), ORA: 49.04 (+0.52), UBNT: 53.17 (+1.10), LGND: 106.19 (-0.85)

Ormat Technologies Reports a Double-Digit Growth in Revenues, Net Income, and Adjusted EBITDA in the Second Quarter
GlobeNewswire - Tue Aug 02, 3:59PM CDT
Ormat Technologies, Inc. (NYSE:ORA) today announced financial results for the second quarter ended June 30, 2016.
ORA: 49.04 (+0.52)

Clean Energy Stocks to Report Earnings on Aug 2: ENPH, ORA
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:34AM CDT
A couple of clean energy stocks that are scheduled to report second-quarter earnings on Aug 2: ENPH, ORA
ENPH: 1.82 (unch), ORA: 49.04 (+0.52)

Zacks Investment Ideas feature highlights: Ormat Technologies, Hanwha Q Cells, EnerNOC, Badger Meter and Esco Tech
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Zacks Investment Ideas feature highlights: Ormat Technologies, Hanwha Q Cells, EnerNOC, Badger Meter and Esco Tech
ORA: 49.04 (+0.52), BMI: 66.46 (+0.46), ENOC: 5.62 (+0.01), ESE: 45.97 (+0.56), HQCL: 12.01 (+0.21)

5 Cleantech Stocks for your Portfolio
Jeremy Mullin - ZACKS - Mon Jun 20, 1:13PM CDT
5 Cleantech Stocks for your Portfolio
TSLA: 197.78 (-2.99), FSLR: 38.18 (-0.26), ORA: 49.04 (+0.52), BMI: 66.46 (+0.46), ENOC: 5.62 (+0.01), ESE: 45.97 (+0.56), HQCL: 12.01 (+0.21)

Ormat Technologies Secures $36 Million Supply & EPC Contracts for a Geothermal Power Plant in New Zealand
GlobeNewswire - Thu May 19, 8:03AM CDT
Ormat Technologies, Inc. (NYSE:ORA) today announced that one of its subsidiaries has signed a $36 million Supply, Engineering, Procurement and Construction, (EPC) contracts, with Eastland Group for the Te Ahi O Maui geothermal project located near Kawerau, New Zealand. The construction of the project is expected to be completed in 2018.
ORA: 49.04 (+0.52)

Ormat Technologies Up 20.9% Since SmarTrend Uptrend Call (ORA)
Comtex SmarTrend(R) - Thu May 12, 1:53PM CDT
SmarTrend identified an Uptrend for Ormat Technologies (NYSE:ORA) on January 29th, 2016 at $35.12. In approximately 3 months, Ormat Technologies has returned 20.90% as of today's recent price of $42.46.
ORA: 49.04 (+0.52)

Global Cyber Alliance Joins Forces With M3AAWG to Drive Industry Adoption of Cybersecurity Solutions
Marketwired - Wed May 04, 12:14PM CDT
SAN FRANCISCO, CA--(Marketwired - May 4, 2016) - Global Cyber Alliance -- an organization founded by the New York County District Attorney's Office, the City of London Police and the Center for Internet Security -- will be collaborating with M3AAWG to push the security community to more quickly adopt concrete, quantifiable practices that can reduce online threats. The non-profit GCA has joined the Messaging, Malware and Mobile Anti-Abuse Working Group, which develops anti-abuse best practices based on the proven experience of its members, and M3AAWG has become a GCA partner for the technology sector.
T: 40.95 (-0.01), ORA: 49.04 (+0.52), LNKD: 192.80 (+0.07), CMCSA: 66.16 (+0.27), ORAN: 15.30 (+0.26), CTL: 27.94 (+0.20), CTCT: 32.01 (+1.39)

Ormat to Ring Opening Bell at New York Stock Exchange; Adjusts Conference Call Time to Accommodate
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Ormat Technologies, Inc. (NYSE:ORA) today announced that its senior management will ring the opening bell at the New York Stock Exchange on May 5, 2016. To accommodate this request, Ormat has moved the starting time for its first quarter 2016 financial results conference call from 9 a.m. to 10 a.m. EDT.
ORA: 49.04 (+0.52)

Ormat Technologies Has Returned 24.3% Since SmarTrend Recommendation (ORA)
Comtex SmarTrend(R) - Wed Apr 27, 1:06AM CDT
SmarTrend identified an Uptrend for Ormat Technologies (NYSE:ORA) on January 29th, 2016 at $35.12. In approximately 3 months, Ormat Technologies has returned 24.32% as of today's recent price of $43.66.
ORA: 49.04 (+0.52)

This Potential Asset Sale Reflects Chevron's Pragmatic Approach to Renewables
Jay Yao, The Motley Fool - Motley Fool - Fri Apr 22, 1:10PM CDT
Geothermal Plant. Source: Flickr. According to Bloomberg, Chevron (NYSE: CVX) is considering selling its Asian geothermal assets for as much as $3 billion. Malakoff Corp., Ormat Technologies  (NYSE: ORA), and the sovereign fund China...
ORA: 49.04 (+0.52), CVX: 100.93 (+0.72)

3 Attractive Income Stocks Whose Dividends Could Double
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 19, 7:19AM CDT
Image source: Flickr user TaxCredits.net.  Dividend stocks can be the foundation of a great retirement portfolio. Not only do the payments put money in your pocket, which can help hedge against any dips in the stock market, but they're usually a...
ORA: 49.04 (+0.52), PDCO: 46.89 (+0.86), NDAQ: 71.67 (+0.03)

Ormat Technologies, Inc. to Host Conference Call and Webcast for First Quarter 2016 Earnings Results
GlobeNewswire - Mon Apr 18, 8:36AM CDT
Ormat Technologies, Inc. (NYSE:ORA) plans to announce its first quarter 2016 earnings results in a press release that will be issued on Wednesday, May 4, 2016 after the market close. The Company has scheduled a conference call to discuss the results at 9 a.m. EDT on Thursday, May 5, 2016.
ORA: 49.04 (+0.52)

Covanta Unit Buys Facility, Expands Southeast U.S. Presence
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 2:35PM CDT
Covanta's (CVA) unit acquired a material processing facility in Augusta, GA, and further expanded its operations in Southeast U.S.
HYGS: 5.50 (unch), CVA: 15.22 (+0.38), ORA: 49.04 (+0.52)

LACNIC and the Latin American Operational Security Community Joins Forces With M3AAWG to Combat Online Threats
Marketwired - Fri Apr 01, 3:00AM CDT
LACNIC, the regional Internet registry for the Latin America and Caribbean region, has joined the Messaging, Malware and Mobile Anti-Abuse Working Group to collaborate on global cybersecurity issues. LACNIC is also the convening forum for the LAC Network Operators Group; LACSEC, the region's Network Security Forum; and LAC-CSIRT, a regional security incident response forum. As part of a mutual partnership to fight online threats, M3AAWG has also joined LACNIC to engage with these service providers and online security communities.
T: 40.95 (-0.01), ORA: 49.04 (+0.52), LNKD: 192.80 (+0.07), CMCSA: 66.16 (+0.27), ORAN: 15.30 (+0.26), CTL: 27.94 (+0.20), CTCT: 32.01 (+1.39)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading